Oral Abstract: Breakthroughs not outbreaks - ID and PTLD
Friday September 19, 2025 from 13:35 to 15:05
MOA 4
Moderators
Lectures
-
227.1 Prevention of human papillomavirus (HPV) infection in pediatric kidney (KTx) and liver transplant recipients (LTx) and in pediatric patients with advanced chronic kidney disease (CKD): a prospective, multicenter vaccine surveillance trial (HPVaxResponse study)Dr. Alexander Fichtner, Germany
-
227.2 Multicenter Prospective Cohort Study of CMV T cell Immunity and First post-transplant CMV DNAemia in Pediatric Solid Organ Transplant RecipientsDaniel Dulek, United States
-
227.3 Complete withdrawal of immunosuppression and long-term graft function in pediatric liver recipients who developed PTLD or EBV infectionDr. Dorota Broniszczak-Czyszek, Poland
-
227.4 Impact of Epstein Barr Virus (EBV) status of lesions, 2016 WHO histologic grade and time of onset on outcome of Post-Transplant Lymphoproliferative Disorder (PTLD) in pediatric solid organ transplant (SOT) and hematopoietic stem cell transplant (HCT) recipients: Results of a prospective/retrospective multicenter studyMichael Green, United States
-
227.5 Pretransplant BK Virus Immunity in Pediatric Kidney Transplantation: Predictive Markers and Role of IVIg ProphylaxisDr. Charlotte Duneton, France
-
227.6 Surveillance of Post-Transplant Lymphoproliferative Disorder in Pediatric Solid Organ Transplant RecipientsDr. Sonya R Kowalczyk, United States
-
227.7 Adoptive cell therapy based on CD45RO+/RA- memory lymphocites infusions to treat BK virus-associated nefropathy in kidney transplant patients.Dr. Alejandro Zarauza Santoveña, Spain
-
227.8 Neonatal acute liver failure secondary to enteroviruses: Outcome with or without liver transplantationDr. Sharath M Manya, United Kingdom
-
227.9 The role of the fungal biomarker Beta-D-Glucan (BDG) in diagnosing and guiding antifungal prescribing for fungal infections in paediatric liver and multivisceral transplant recipientsDr. Sharath M Manya, United Kingdom